Ernexa Therapeutics Inc. · NASDAQ:ERNA
Ernexa Therapeutics — Investor Presentation (October 2026)
19 slides from Ernexa Therapeutics's investor presentation, Oct 15, 2026
Slide 1: Breaking Through Defenses, Delivering Hope
ErneX Therapeutics Breaking Through Defenses, Delivering Hope Modulating Immune System to Target Cancer Throug| Synthetic Induced Mesenchymal Stromal Cell (iMSC) ef 7. October 2026 Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement ‘This presentation (this “Presentation”) and any oral statements made in connection with this Presentation are for informational purposes only andl do not constitute an offerto sella solicitation of an offer to buy, ora recommendation to purchase ary equity, debt or other secur
Slide 3: A Highly Experienced Leadership Team
A Highly Experienced Leadership Team ErmeXa Sanjeev Luther, MBA; President and CEO: 25-30 years in drug development and strategy; raised >$100M, led a clinical-stage acquisition, and advanced oncology innovation (11 INDs, 2 NDAs) Robert Pierce, MD; Chief Scientific Officer: 20+ years across academia
Slide 4: Our Mission
OUR MISSION e ° Providing Hope We are developing innovative cell therapies to bring new treatment possibilities to people facing difficult-to-treat cancers ts Starting with ovarian cancer
Slide 5: The Ernexa Opportunity
The Ernexa Opportunity Engineered induced mesenchymal stromal cell (iMSC) therapy platform with compelling preclinical data and a clear path towards clinical trials TECHNOLOGY PLATFORM LEAD ASSET Synthetic iMSCs ERNA-101 Immune Activation Within Tumors Designed to Turn “Cold” Tumors “Hot” Synthetic
Slide 6: Pipeline in a Product: Next-Generation iMSC Therapy Across Solid Tumors
peline in a Product: ing Next-Generation iMSC Therapy Across Solid Tumors Asset Indication Combinations Preclinical Phase1 Phase2 Upcoming Milestones Platine et 5 IND Submission olizuma Resistant, ae Ovarian Cancer i‘ pitt study by Bevacizumab OY: (PROC) Q1 2027 ERNA-101 Other Gynecological Preclini
Slide 7: Mechanism of Action of ERNA-101: Utilizing the Intrinsic Tumor-Homing Ability
Mechanism of Action of ERNA-101: Utilizing the Intrinsic Tumor-Homing Abi A Untreated Tumor (Colc!) B ERNA-101-Treated Tumor (Hot) Localized IL7 / ILS: proliferation and survival Activated (cxcR3+) Cold tumor RNA-1OT Poor T/NK infiltration 2 2, Edge T cells Robust response SP toanthPD-T ity of MSCs
Slide 8: ERNA-101: Engineered iMSC Based Therapy Designed to Address Shortcomings of Other Approaches
ERNA-101: Engineered iMSC Based Therapy Designed to Address the Shortcomings of Other Therapeutic Approaches TREATMENT APPROACI Small-molecule therapies Monoclonal antibodies Antibody-drug conjugates (ADCs) Adoptive cell Therapies Natural MSCs (investigational) ORB Recombinant IL-7/1 Oncolytic virus
Slide 9: Lead Indication: Platinum-Resistant Ovarian Cancer (PROC)
Lead Indication: Platinum-Resistant Ovarian Cancer (PROC) PROC is a subset of recurrent ovarian cancer, defined by disease progression within six months after completing platinum-based chemotherapy cal | 7,000 ~25% patients U.S. patients with PROC” Affected in first relapse Estimated drug-treatable
Slide 10: ERNA-101 Treatment Leads to Substantial Accumulation of IL-7_IL-15 & T-Cell Infiltration
ERNA-101 Treatment Leads to Substantial Accumulation of IL-7_IL-15 & Significant Increase in T-Cell Infiltration into the TME Ovarian tumor-bearing mice treated with PBS, GFP-iMSC or ERNA-101 (IL-7_IL-15-iMSCs) CYTOKINE EXPRESSION IN TUMORS INCREASED T-CELL ACCUMULATION ~3% CD4Tcells ~5X CD8T cells
Slide 11: ERNA-101 + Anti-PD-1 Demonstrated Complete Tumor Clearance and 100% Survival
e (Duraiswamy etal, 2013). ErneXa TME and substantially enhance tho IP ERNA-101 + Anti-PD-1 Demonstrated Complete Tumor Clearance and 100% Survival in an Ovarian Cancer Model ERNA-101 + anti-PD-1 in a preclinical ID8'U®-°¥4 syngeneic mouse model |]PBS MControliMSC MERNA-101 MPD1Ab MERNA-101+PD1 Ab 1
Slide 12: IND Filing Status Update: GLP Safety Studies Completed with a Clean Profile
IND Filing* Status Update: GLP Safety Studies Completed with a Clean Profile Immune activation at the tumor site, with broader changes in circulating immune cells REPEAT-DOSE TOXICOLOGY TUMORIGENICITY BIODISTRIBUTION No treatment-related No tumors or ectopic Tumor-selective adverse findings tissue o
Slide 13: Manufacturing & CMC Readiness
Manufacturing & CMC Readiness: Manufacturing Process Finalized - GMP Engineering Run Underway ERNA-101 manufacturing transferred to kincellis 01 Manufacturing transferred Comparable IL-7 and IL-15 activity Potency of PD3 and PDS as secreted SEAP Process development and analytical methods were Sstabl
Slide 14: ERNA-101: Upcoming First in Human Phase Study MD Anderson Cancer Center
ERNA-101: Upcoming First in Human Phase 1 Study MD Anderson Center First-in-human, open-label study evaluating ERNA-101 (IP) in monotherapy and combination treatment H ERNA-101 (IP) Monotherapy Dose-Escalation - Q3W_ PART 1 Monotherapy dose-escalation Baseline Assessment FollowUp if it ‘Sean and Bio
Slide 15: Clinical Data Can Unlock Significant Value
Clinical Data Can Unlock Significant Value Selected oncology transactions demonstrate pharma investment in differentiated clinical programs @ GILEAD TWeULzs Acqui ‘Announced April7, 2026" TUB-040 NaPi2b-directed ADC. Platinum-resistant ovarian cancer/ NSCLC. ‘STAGE AT ANNOUNCEMENT $11.4B {$1.28 upfr
Slide 16: 2026: A Year of Execution
2026: A Year of Execution Building the scientific, manufacturing and organizational foundation for clinical development PROGRESS OVER THE PAST 12 MONTHS COMPLETE FDA pre-IND meeting FDA feedback incorporated into the development strategy EmeXa COMPLETE IND-enabling studies Preclinical package comple
Slide 17: Developmental Plan for Next Months; Driving ERNA-101 Toward Human Data in PROC
Developmental Plan for Next 24 Months; Driving ERNA-101 Toward Human Data in PROC Upcoming clinical catalysts are expected to drive value and bring new hope to patients KEY DEVELOPMENT MILESTONES Q4 2026 Q1 2027 Q4 2027 Q2 2028 e e e e IND First patient Interim Final submission dosed results results
Slide 18: Investment Summary
Investment Summary Compelling Data. Near-Term Catalysts. Significant Potential. SURVIVAL DEMONSTRATED Complete tumor clearance ERNA-101 + anti-PD-1 Preclinical ovarian cancer model ot ErneXa NEWHOPE FOR PROC Addressing a significant unmet need in PROC Current SOC shows limited survival benefit with
Slide 19: Ernexa Therapeutics
ErneXa Therapeutics Breaking Through Defenses, Delivering Hope We aim to change what it means to live with ovarian cancer, turning years of treatment into years of living e§ For further details, please contact: Sanjeev Luther, President and CEO at: ‘Sanjeev.Luther@erexatx.com
Ernexa Therapeutics — Investor Presentation (October 2026) on 6ix